Abstract
Genomic amplification and oncoprotein overexpression of Her-2/neu was studied on ultrasound core needle biopsy specimens of the infiltrative ductal carcinomas of the breast. We performed “two colour” fluorescence in situ hybridization (FISH) for Her-2/neu and chromosome 17 and compared the FISH results with the immunohistochemical overexpression of Her-2/neu protein by 2 antibodies (DAKO HercepTest and the BioGenex monoclonal antibody AM 134-5M). Furthermore, following radical mastectomy with axillary dissection, Her-2/neu status of the patients were compared with the well known histopathological prognostic factors such as histologic grade, tumor stage, lympho/ vascular invasion, surgical margin status and Paget’s disease. Amplification was demonstrated 27% of the cases. Her-2/neu protein overexpression was detected in 47% and 80% of the cases with CB11 and HercepTest respectively. We revealed statistically significant association between the tumor, oncoprotein expression and oncogene amplification (p<0.05). The results of our study showed that combination of IHC and FISH methods enhances the evaluation of tumor genetics at both gene and protein level for the analysis of Her-2/neu in breast carcinoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Pettine S, Place R, Babu S, et al: Stereotactic breast biopsy accurate, minimally invasive, and cost effective. Am J Surg 171:474–476, 1996.
Wallace JE, Sayler C, McDowell NG, et al: The role of stereotactic biopsy assessment of nonpalpable breast lesions. Am J Surg 172:471–473, 1996.
Timothy WJ, Kalliopi PS, Prioleau JE, et al: Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor. Mod Pathol 11:259–264, 1998.
Bargmann CI, Hung MC, Weinberg RA: The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319:226–230, 1986.
Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: correlation of relapse and survival with amplification of theHER-2/neu oncogene. Science 235:177–182, 1987.
Evans AJ, Pider SE, Ellis IO, et al: Correlations between the mammographic features of ductal carcinoma in situ (DCIS) and C-erbB-2 oncogene expression. Nottingham Breast Team: Clin Radiol 49:559–562, 1994.
Pauletti G, Godolphin W, Press MF, et al: Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13:63–72, 1996.
Bankfalvi A, Simon R, Brandt B, et al: Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use. Histopathol 37:411–419, 2000.
Jimenez RE, Wallis T, Tabasczka P, et al: Determination of Her-2/neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 13:37–45, 2000.
Press MF, Bernstein L, Thomas PA, et al: HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15:2894–2904, 1997.
Persons DL, Borelli KA, Hsu PH: Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluo-rescence in situ hybridization. Mod Pathol 10:720–727, 1997.
Hoang MP, Sahin AA, Ordonez NG, et al: Her-2/neu gene amplification compared with Her-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol 113:852–859, 2000.
Ratcliffe N, Wells W, Wheeler K, et al: The combination of in situ hybridization and immunohistochemical analysis: an evaluation of Her2/neu expression in paraffin-embedded breast carcinomas and adjacent normal appearing breast epithelium. Mod Pathol 10:1247–1252, 1997.
Scorilas A, Yotis J, Strvolemos K, et al: c-erbB-2 overexpression may be used as an independent prognostic factor for breast cancer patients. Anticancer Res 15:1543–1648, 1995.
An H-X, Niederacher D, Dominik SI, et al: Int-2 and c-erbB-2 gene amplification detected in 70 frozen human breast carcinomas by quantitative polymerase chain reaction. Anticancer Res 17:3133–3136, 1997.
Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712, 1989.
Hopman AHN, Ramaekers FCS, Raap AK, et al: In situ hybridization as a tool to study numerical chromosome aberrations in solid bladder tumors. Histochem 89:307–316, 1988.
De Potter CR, Schelfout AM: The neu-protein and breast cancer. Virchows Arch 426:107–115, 1995.
Ross JS, Fletcher JA: The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 16:413–428, 1998.
Press MF, Hung G, Godolphin W, et al: Sensitivity of HER-2/neu antibodies in archival tissue samples potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54:2771–2777, 1994.
Tubbs RR, Pettay JD, Roche PC, et al: Discrepancies in clinical laboratory testing of eligibility for transtuzumab therapy: apparent immunohistochemical false positives do not get the message. J Clin Oncol 15:2714–2721, 2001.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kaya, H., Ragazzini, T., Aribal, E. et al. Her-2/neu gene amplification compared with HER-2/neu protein overexpression on ultrasound guided core-needle biopsy specimens of breast carcinoma. Pathol. Oncol. Res. 7, 279–283 (2001). https://doi.org/10.1007/BF03032384
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF03032384